Land Retained Mandates 60–90 Days Before Roles Go Public

Market Signals & Catalysts

Verifiable events (FDA filings, CMS citations, PE roll-ups, facility expansions) triggering immediate hiring needs.

Probable Executive Roles

The exact C-suite, VP, and specialized leadership vacancies created by each event before they are publicly posted.

Decision-Maker Identification

Direct access details for the executive who holds the hiring authority for the opportunity.

Pitch-Ready Outreach Angles

Strategic framing that allows your partners to open conversations as domain experts rather than generic recruiters.

Brief sample preview

See what your brief looks like.

Gateway Regional Medical Center

Granite City, IL · Aug 11, 2026

Immediate Jeopardy citation after the hospital diverted a cardiac arrest patient without state approval because payroll bounced and staff did not show up. Parent company AHS personally loaned $1 million to cover the August 1 payroll.

What happened

The CNO told state inspectors the hospital "had a payroll issue and were unsure how many staff were going to even come in that evening." The diversion happened at 5:02 PM. State approval did not come until 5:37 PM. The patient, five weeks post quadruple bypass surgery, was rerouted to another hospital and admitted to the ICU. Parent company AHS, led by CEO Michael Sarian out of Los Angeles, personally loaned $1 million to cover the August 1 payroll. Gateway CEO Joe Ottolino, described as a veteran hospital executive, was installed recently as part of a new leadership team. The hospital has rewritten its diversion policy in consultation with IDPH, but the underlying problem is financial: bounced paychecks caused a staffing crisis that caused a patient safety crisis.

Outreach angle

Your CNO told inspectors she did not know ambulance diversion required state approval. A cardiac arrest patient was rerouted because payroll bounced and staff did not come in. The IJ citation is the symptom. The root cause is financial instability driving staffing failures driving patient safety failures. The hospital needs a CNO who has operated under CMS scrutiny before and can rebuild nursing operations while the financial restructuring runs underneath. That profile is specific enough that internal recruitment will not close it. A search firm that understands regulatory remediation timelines can map the right candidates in days, not months.

Lead asset · Remediation Leadership Readiness Brief

IU Health Fort Wayne

Fort Wayne, IN · Aug 19, 2026

$200M+ new hospital opening May 2027. 140 beds, six operating rooms, 17 emergency exam rooms, three cardiac catheterization labs, four endoscopy rooms. 270+ nursing positions in recruitment, total staffing above 600 team members and 60 providers.

What happened

The system is recruiting 270+ nursing positions across ICU, progressive care, medical-surgical, OR, cath lab, and emergency care, alongside an attached medical office building. Half of physician recruits are targeted to be new to northeast Indiana. The system is building clinical training, residency opportunities, and tuition support programmes alongside the facility. Dr. Greg Johnson, Chief Physician Executive of Growth Markets, and John Bowen, Chief Growth Markets Officer, are leading the effort. Opening is nine months away, which means the executive leadership team for the facility is being finalised now.

Outreach angle

You are nine months from opening a 140-bed hospital with six ORs and three cath labs. The nursing pipeline is underway with 270+ positions in recruitment, but the physician and executive leadership team determines whether this facility opens on time and operates at the clinical standard IU Health’s brand demands. Half your physician targets are new to northeast Indiana, which means you are competing with every other health system in the Midwest for the same relocation-ready candidates. The search firms positioned to fill CMO, ED Director, and cath lab leadership now are the ones you will call when the volume ramps post-opening.

Lead asset · Go-Live Facility Staffing Blueprint

Memorial Healthcare System

Hollywood, FL · Aug 14, 2026

Four executive departures across three facilities in one week. CEO of Joe DiMaggio Children's Hospital terminated after eight years. CMO resigned days later. CEO of Memorial Hospital West retired. COO of Memorial Hospital West terminated.

What happened

Caitlin Stella, CEO of Joe DiMaggio Children's Hospital, was terminated after eight years and CMO Dr. Ronald Ford resigned days later. At Memorial Hospital West, CEO Joseph Stuczynski retired and COO Judy Frum was terminated. Stephen Demers moved from Memorial Miramar to fill the West role, creating a second CEO opening at Miramar, now filled by Felicia Turnley. The system itself is still operating under interim CEO Shane Strum, who is also the CEO of Broward Health System. Five leadership seats changed hands in one week, with new leaders at two hospitals who will each build their own teams over the next 90 days.

Outreach angle

Five leadership seats changed hands in one week across three facilities, and the system itself is still running under an interim CEO. Each new hospital CEO will build their own team in the next 90 days, which means VP and director-level searches are coming before those roles are even posted. The firms that map the talent market now will be positioned when those searches go live.

Lead asset · Pre-Market Talent & Compensation Benchmark

UChicago Medicine

Chicago, IL · Jul 14, 2026

Recruited four senior neurosurgeons simultaneously as part of department chair Mohamad Bydon’s push to expand complex neurosurgical care across the system. This is not backfill. Four hires at once signals a full programme build.

What happened

The department installed robotic spine surgery (iMRI) and recruited a new spine chief, neuro-oncology chief, trauma chief, and vascular chief in a single wave. The system is building a national referral programme for complex neurosurgical cases, which means additional hires are likely as volume grows. Academic medical centres at this level recruit through retained search because the candidate pool for fellowship-trained neurosurgical subspecialists willing to join an academic programme is extremely narrow.

Outreach angle

Hiring four neurosurgeons at once is a programme build, not backfill. A department chair who just installed new chiefs in spine, neuro-oncology, trauma, and vascular neurosurgery within a single quarter is building a national referral programme, which means the next wave of hires is already in planning. The subspecialty profiles needed, fellowship-trained neurosurgeons willing to join an academic programme in a competitive Chicago market, represent one of the narrowest candidate pools in physician recruitment. A search firm that already has relationships in academic neurosurgery can shorten the timeline from nine months to four.

Lead asset · Pre-Market Talent & Compensation Benchmark

Summit Spine & Joint Centers / Wellspring Capital

Southeast US, five states · Jul 14, 2026

Third acquisition in three years. Acquired Southeast Neurology & Pain Management, adding Thomasville GA, Tallahassee FL, and Panama City FL locations. Platform now operates 55 clinics and 21 ASCs across five states.

What happened

Backed by Wellspring Capital, formerly MSouth Equity Partners, the platform now spans Georgia, North Carolina, South Carolina, Florida and Tennessee. CEO and founder Dr. Amit Patel is actively seeking physician partners for continued expansion. Each acquisition creates leadership restructuring and physician recruitment needs at the acquired practice while the platform simultaneously recruits surgeons and pain physicians to grow volume across existing locations. The pace of acquisition, three deals in three years, means the integration and recruitment cycle is continuous.

Outreach angle

Three acquisitions in three years across five states means you are running integration and physician recruitment simultaneously at every stage. Each new practice you absorb needs its medical director reviewed, its operations leadership assessed, and its surgeon roster evaluated for growth potential. The ASC portfolio alone, 21 centres, creates a continuous need for credentialed surgeons across multiple geographies. A search firm that understands PE roll-up dynamics in spine and pain management can map physician candidates across your expansion corridor before each acquisition closes.

Lead asset · Portfolio Integration & Cascade Leadership Map

Novo Nordisk Fill-Finish Facility (ex-Catalent)

Bloomington, IN · Aug 10, 2026

OAI classification for the second consecutive year. FDA re-inspection in April 2026 found eight Form 483 observations including persistent contamination and quality systems deficiencies. Scholar Rock pulled the facility from its BLA filing for apitegromab.

What happened

This is the facility formerly known as Catalent Bloomington, acquired by Novo Nordisk. It has now received Official Action Indicated classification in back-to-back years, which means a full year of investment in remediation failed to satisfy the FDA. Eight observations in April included contamination that Novo described as detected through normal manufacturing controls, but the FDA classified the finding as an unacceptable state of compliance. The downstream impact is significant: Scholar Rock removed the facility from its BLA for a spinal muscular atrophy therapy and is proceeding with a backup fill-finish site. Regeneron has also been affected by quality issues at this facility in prior years. For the CDMO itself, repeat OAI means client confidence is eroding. The VP of Quality, Director of Sterility Assurance, and potentially the Site Director are all under board-level scrutiny.

Outreach angle

Your facility has received OAI classification two years in a row. The quality leadership installed after the first finding has not remediated the issues. Two biopharma clients have publicly pulled or restructured their filings because of your site’s compliance status. The next inspection cycle will determine whether this facility can continue operating as a commercial fill-finish CDMO, and the FDA will be looking specifically at whether the quality leadership team has changed and whether the new team has a demonstrable track record of FDA remediation at comparable sterile manufacturing sites.

Lead asset · Remediation Leadership Readiness Brief

Cogent Biosciences

Aug 11, 2026

Three simultaneous NDA filings. PDUFA November 30, 2026 for GIST under Priority Review. PDUFA December 30, 2026 for non-advanced SM. Third NDA submitted June 30, 2026. $792M cash, $400M ATM opened at $42.39/share.

What happened

Cogent is a clinical-stage biotech executing something rare: three simultaneous product launches from a single company. The GIST indication has a Priority Review PDUFA on November 30, meaning the FDA decision is less than four months away. A second PDUFA follows on December 30 for non-advanced systemic mastocytosis. The company has $792M in cash after opening a $400M ATM facility, signalling confidence in approval. The commercial build is visible in the financials: G&A more than doubled year-over-year to $31.8M, which reflects field force, patient access infrastructure, and market access spend landing on the P&L six months before the first prescription. The company has hired and onboarded its full customer-facing organisation including clinical account managers, patient access navigators, patient educators, and medical affairs staff.

Outreach angle

Three NDAs pending with two PDUFA dates within 30 days of each other is an unprecedented launch execution challenge. The commercial organisation is hired, but launching two indications simultaneously in Q4 2026 while preparing a third means every gap in the field team, every delay in training, and every missing regional leader compounds across all three programmes. The firms positioned to fill launch operations and post-approval roles before November are the ones that will be in the room when the approval announcements drop.

Lead asset · Go-to-Market Leadership Blueprint

Implantica / RefluxStop

Liechtenstein, US launch · Aug 21, 2026

FDA PMA approval granted, US commercial launch beginning. First implant-based GERD treatment approved in the US. European infrastructure of 60+ Centers of Excellence and 1,800 patients treated across nine countries, but US operations are being built from scratch.

What happened

Implantica received PMA approval for RefluxStop, a surgically implanted device for gastroesophageal reflux disease, on August 20. The company has operated commercially in Europe for several years, which gives it a clinical evidence base and commercial playbook that most first-time device launchers lack. But the US market is fundamentally different: reimbursement landscape, surgeon training requirements, KOL relationships, and distribution infrastructure all need to be built from zero. The Q2 interim report confirms that expansion of the US organisation and establishment of logistics and distribution infrastructure is already underway. The initial rollout will target selected leading US centres and reflux surgeons, which means the first hires will be in clinical education and key accounts, followed by a broader field sales build as surgeon adoption grows.

Outreach angle

You have a PMA-approved device, five-year clinical outcomes, and 60 European Centers of Excellence, but zero US commercial infrastructure. The US reimbursement landscape, surgeon training pathway, and KOL network are fundamentally different from Europe. The firms that have placed US commercial leadership for European MedTech companies entering the US market understand the specific profile needed: someone who has built a US device franchise from a standing start, ideally in a surgical specialty with a similar adoption curve. That profile is narrow and competitive, which is why retained search outperforms internal recruitment for US market entry roles.

Lead asset · Go-to-Market Leadership Blueprint

Xcellon Biologics

Beltsville, MD · Aug 10, 2026

Acquired a 40,000 sq ft GMP manufacturing facility from NextCure. Two 1,000L single-use bioreactors, dedicated bioconjugation suite, high-throughput process development with advanced robotics. GMP operations beginning December 2026.

What happened

Xcellon is a company that launched in 2025 and just made a transformational acquisition: NextCure’s entire GMP biologics manufacturing facility. This is not an incremental expansion. It is a company that went from development-stage CRDMO to end-to-end clinical manufacturer in a single transaction. The facility includes two 1,000L single-use bioreactors, a bioconjugation suite (their core specialty), robotics-enabled process development, and full analytical capabilities. GMP operations are planned for December 2026, which means the leadership team to run the facility needs to be in place within the next 90 days. A company this early-stage, with this level of ambition, and with a hard GMP deadline in four months, will not fill VP and Director-level roles through job postings.

Outreach angle

You acquired a 40,000 sq ft GMP facility and plan to begin operations in December 2026. That is four months to hire and onboard a Site Director, VP of Quality, Director of Manufacturing, and Director of Validation, all roles that require candidates with hands-on GMP biologics experience and a track record satisfying FDA pre-approval inspections. The talent pool for bioconjugate and ADC manufacturing leadership is one of the smallest in the industry, and every month of delay between now and December compresses your validation timeline.

Lead asset · Capacity Scale-Up Staffing Blueprint

AusperBio Therapeutics

San Francisco, CA · Aug 28, 2026

$120M Series C, $360M total raised since 2024. Near-commercial stage. Phase 3 registrational programme for AHB-137 in chronic hepatitis B. RA Capital Management participating. Funding commercialisation readiness and pipeline expansion.

What happened

AusperBio has raised $360 million in two years, which puts it in the upper tier of clinical-stage biopharma funding. The company describes itself as near-commercial, a term that signals the transition from R&D-led organisation to one that needs commercial infrastructure. The Phase 3 registrational programme for AHB-137 is the lead asset, and the Series C explicitly funds commercialisation readiness alongside continued development of AHB-171, an siRNA candidate on their proprietary Au-HALO delivery platform. RA Capital’s participation adds institutional validation. The CCO, VP of Market Access, VP of Medical Affairs, and Head of Commercial Operations are all roles that should be placed 12-18 months before anticipated approval. At $360M raised and Phase 3 underway, the capital is committed and the hiring is funded.

Outreach angle

$360 million raised in two years and a Phase 3 registrational programme underway means the board has committed to commercialisation. The question is no longer whether the company will build a commercial team, it is when and who leads it. Hepatitis B is a global market with complex payer dynamics, established competition, and a patient population that requires a sophisticated medical affairs and market access strategy. The CCO and VP of Market Access need to be in place 12-18 months before anticipated approval to design the launch architecture.

Lead asset · Go-to-Market Leadership Blueprint